Viatris Inc reaffirmed its full-year revenue forecast on Monday and said it was on track to achieve about $500 million in annual sales from its newly launched products, sending its shares up ...

Drugmaker Viatris forecast annual revenue above Wall Street estimates on Wednesday, banking on strong demand for its branded drugs such as Yupelri for lung disease and Breyna for asthma. Viatris ...

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares ...

Viatris' R&D spending was $207.9 million in Q2 2023, up 28.3% year-over-year due to increased investment in developing product candidates such as MR-148 and MR-141.

A month has gone by since the last earnings report for Viatris (VTRS). Shares have lost about 3.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ...

Viatris is paying about $300 million to acquire Famy Life Sciences, according to the Economic Times, a business newspaper in India, where Famy is based.The Times reported that the Taparia family ...

Viatris will spend as much as $335 million to settle opioid-related claims against the Canonsburg-based pharmaceutical company. The proposed settlement over nine years would come in the form of ...

XULANE LO showed a 3.7% cumulative pregnancy rate over 13 cycles with strong patch adhesion and low severe site reactions. MR-107A-02 led to higher opioid-free rates: 72.6% post-herniorrhaphy vs ...

Robert J. Coury will leave his role as executive chairman of Viatris by the end of the year after serving in the job for a second time at the Canonsburg-based pharmaceutical company.

VTRS agreed to acquire OYST and Famy Life Sciences for combined $700 million to $750 million. OYST shareholders receive $11 plus a CVR (potentially worth $1-$2) per share.